Cas:622369-42-0 6-Methoxy-7-(2-methoxyethoxy)-4-oxo-1,4-dihydro-3-quinolinecarbon itrile manufacturer & supplier

Chemical Name:6-Methoxy-7-(2-methoxyethoxy)-4-oxo-1,4-dihydro-3-quinolinecarbon itrile

CAS.NO:622369-42-0

Synonyms:4-hydroxy-6-isopropylquinoline-3-carboxylic acid

Molecular Formula:C₁₄H₁₄N₂O₄

Molecular Weight:274.27200

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:436.348ºC at 760 mmHg

Density:1.297g/cm3

Index of Refraction:1.58

PSA:84.34000

Exact Mass:274.09500

LogP:1.43358

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4-hydroxy-6-isopropylquinoline-3-carboxylic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-hydroxy-6-isopropylquinoline-3-carboxylic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-hydroxy-6-isopropylquinoline-3-carboxylic acid Use and application,4-hydroxy-6-isopropylquinoline-3-carboxylic acid technical grade,usp/ep/jp grade.

Related News: Standard respiratory support therapies are used to treat the symptoms and wait for the virus to be cleared by itself. 6-Methoxy-7-(2-methoxyethoxy)-4-oxo-1,4-dihydro-3-quinolinecarbon itrile manufacturer ��We believe the iLet Bionics Pancreas System represents a true breakthrough therapy for the management of glycemia, particularly in type 1 diabetes,�� said Ed Damiano, President and CEO of Beta Bionics. ��We are partuclarly excited by the possibility that the iLet may be able to provide safer and more effective therapy in far more people than current therapies due to its simplicity of use.�� 6-Methoxy-7-(2-methoxyethoxy)-4-oxo-1,4-dihydro-3-quinolinecarbon itrile supplier In the current trial, a total of 196 patients were randomly chosen to receive either the vaccine or a placebo. 6-Methoxy-7-(2-methoxyethoxy)-4-oxo-1,4-dihydro-3-quinolinecarbon itrile vendor ��We believe the iLet Bionics Pancreas System represents a true breakthrough therapy for the management of glycemia, particularly in type 1 diabetes,�� said Ed Damiano, President and CEO of Beta Bionics. ��We are partuclarly excited by the possibility that the iLet may be able to provide safer and more effective therapy in far more people than current therapies due to its simplicity of use.�� 6-Methoxy-7-(2-methoxyethoxy)-4-oxo-1,4-dihydro-3-quinolinecarbon itrile factory “Whenever a company hires outside counsel to conduct an inquiry, it’s taken extremely seriously by the Justice Department,” said Paul Pelletier, a former long-time federal prosecutor who used to oversee criminal investigations of corporations.